Small peptidic aldehyde inhibitors of human rhinovirus 3C protease

Small peptidic aldehyde inhibitors of human rhinovirus 3C protease Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 4. Incorporation of P₁ Lactam Moieties as <scp>l</scp>-Glutamine Replacements Design and synthesis of irreversible depsipeptidyl human rhinovirus 3C protease inhibitors Design and structure–activity relationships of novel inhibitors of human rhinovirus 3C protease Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 6. Structure−Activity Studies of Orally Bioavailable, 2-Pyridone-Containing Peptidomimetics Design, synthesis, and evaluation of 3C protease inhibitors as anti-enterovirus 71 agents Evaluation of peptide-aldehyde inhibitors using R188I mutant of SARS 3CL protease as a proteolysis-resistant mutant Substituted Benzamide Inhibitors of Human Rhinovirus 3C Protease:  Structure-Based Design, Synthesis, and Biological Evaluation Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 8. Pharmacological Optimization of Orally Bioavailable 2-Pyridone-Containing Peptidomimetics Non-covalent inhibitors of rhinovirus 3C protease